Voltaren Articles
Spain’s Almirall posts solid performance in 2009, setting basis for sustainable long-term growth
1 March 2010
Myriad to acquire Javelin in stock deal valued at $96 million
21 December 2009
Opana growth drives Endo's profit up 15%
16 March 2009
Javelin signs $71M deal on Dyloject
26 January 2009
Abraxis pays initial $15M for Shimoda
14 April 2008
Javelin
17 March 2008
Javelin's Dyloject added to UK hospital formulary
24 December 2007
Novartis' Voltaren Gel cleared by FDA
29 October 2007
Javelin initiates 2nd Ph III Dyloject study
6 August 2007
Bradley's 1st-qtr 2007 net sales rise 9%
21 May 2007
Japan
9 April 2007
Pennsaid gets FDA approvable letter
8 January 2007
Australia OKs Shire's Solaraze for AK
11 December 2006
India: price-controlled drugs see sales rise
16 October 2006
Stock Commentary - Europe
25 July 2005
Provalis half-year 2004 results in line
7 March 2005
Japan stock market week to February 21
28 February 2005
Fujisawa makes strategic drug transfers ahead of merger
28 February 2005
Bradley closes acquisition of Bioglan
16 August 2004
Bradley to buy Bioglan in $183M deal
21 June 2004
SkyePharma's full-year 2003 sales down 24%
10 May 2004
Teva comments on Biovail dispute
8 March 2004
Provalis narrows losses and improves sales
8 September 2003
Provalis boosted by diagnostic performance
14 July 2003
SkyePharma licenses more Solaraze rights to Shire
20 January 2003
US/S African industry deal aims to cut ADR deaths
10 June 2002
Stock Commentary - Europe
27 May 2002
SkyePharma sells Euro Solaraze right to Shire
20 May 2002
Provalis sees sales, gross profit advance
25 March 2002
Quintiles, the savior of Bioglan?
28 January 2002
Stock Commentary - Europe.
21 January 2002
SkyePharma's Solaraze is launched in USA
14 January 2002
SkyePharma and Astralis in psoriasis pact
7 January 2002
Breathing space for Bioglan
7 January 2002
Breathing space for Bioglan
24 December 2001
SkyePharma and Astralis in psoriasis pact
17 December 2001
Stock Commentary - Europe
29 November 2001
SkyePharma looking to end Solaraze deal with Bioglan
21 November 2001
First launch for Solaraze
17 May 2001
Bioglan sees net leap 85%, sales up 66%
20 April 2001
Novartis looking to get bigger
31 January 2001
Stock Commentary - Europe
11 January 2001
Bioglan buys Hexal products for L16.4 mill
8 January 2001
Stock Commentary - Europe
26 October 2000
SkyePharma wins FDA approval for Solaraze
25 October 2000
SkyePharma wins FDA approval for Solaraze
20 October 2000
Novartis puts in solid 1st-half performance
21 August 2000
Novartis sees launch of cancer drug by 2001
18 April 2000
First Voltaren XL generic approved and launched in USA
24 February 2000
Sincere Pharma set up in China's Jiangsu
7 December 1999
Novartis to increase investment in Spain
26 November 1999
Novartis link-up with Monsanto mooted
10 November 1999
Novartis looking to cut costs in Switzerland
11 August 1999
North Asian markets for OTC analgesics
5 August 1999
US Insurers Ponder COX-2 Inhibitors
23 November 1998
Novartis Restructures After Disappointing First Half
1 September 1998
First Operational Year Strong At Novartis
19 March 1998
Hyal Product Setback Cuts Investor Confidence
12 January 1998
Spanish Drug Move To Boost Health Service Funds
18 November 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
Sales Advance 8% In 1996 At Novartis
3 February 1997
Euro OTC Pain Relief Market Led By Intl Brands
27 January 1997
Interim Financial Results From The USA
18 November 1996
Potential For Growth In Israel's OTC Market
4 November 1996
Novartis Partners 9 Months Figures Disappoint
28 October 1996
Ethical Generics On Target
14 October 1996
James Callahan Resigns From Ciba-Geigy
16 September 1996
Strong Growth From Ciba In 1996 First Half
22 July 1996
Strong Swiss Franc Impacts On Ciba's 1st Quarter
29 April 1996
Rheumatoid Arthritis And Disease Management
22 April 1996
-Diclofenac Sodium 25mg Rescheduling In South Africa
22 April 1996
Novartis Will Be A Leading Player In OTC Market
8 April 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Ciba Health Care Sales Rise 8%
29 January 1996
Ciba' Indian Investment Okayed
22 January 1996
Ciba Gets Positive Nine-Month Reception
23 October 1995
Does Ciba Need A Clearer Strategic Direction?
25 September 1995
Sales Decline 6% At Ciba In 1995 First Half
4 September 1995
Roxane's Generic Diclofenac
17 July 1995
Benefits Of Drug Delivery Systems For Generics
5 June 1995
Record Operating Performance At Ciba
3 April 1995
$25 Bill Latin American Pharma Market In 2000
9 January 1995
World Immunology, Rheumatology Markets
28 November 1994
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
